Executive Summary
Deferring PCI before TAVR is safe on average but not safe for everyone: in the PRO-TAVI SYNTAX substudy (JACC: Cardiovascular Interventions, 466 randomized patients), patients with SYNTAX score above 17 who had PCI deferred suffered the ischemic composite of death, MI, and stroke at 30.9% versus 14.8% with pre-TAVR PCI (adjusted HR 2.43, 95% CI 1.04-5.64), while bleeding fell with deferral across every SYNTAX stratum. A separate Spanish multicenter registry found that conduction system pacing after TAVR cut cardiovascular death or heart failure hospitalization to 9.7% versus 17.6% with right ventricular pacing (HR 0.57) across 466 propensity-matched pairs. Both are post hoc or retrospective, so neither settles anything. Together they complicate the case for a reflexive "TAVR plus staged PCI plus whatever pacemaker the lab defaults to" pathway in patients whose coronary anatomy would otherwise have sent them to the surgeon.
- Conduction system pacing beat RV pacing on heart failure hospitalization after TAVR (7.9% vs 13.9%), with no mortality difference, in a retrospective registry (JACC Cardiovasc Interv).
- JenaValve recalled specific TAVR delivery catheters over safety concerns, a setback for the only dedicated aortic regurgitation platform in late-stage US development (Cardiovascular Business).
- CMS changes to TAVR coverage rules are drawing self-referral questions, the first serious US policy friction on TAVR access since the 2019 NCD (Medscape).
- Severe aortic stenosis was an independent predictor of intraprocedural cardiac arrest in 3.96 million PCIs; 40.5% of those patients died in hospital (NCDR CathPCI).
- Erasmus MC registered SYMMETRY (n=422), testing double-TAP post-dilatation to reduce hypoattenuated leaflet thickening after balloon-expandable TAVI (NCT07872020).
What to watch: Abbott reports Q3 on October 21, the first read on structural heart volumes after the EACTS late-breaking cycle.
Aortic Valve (TAVR/TAVI)
Complex coronary disease is where the all-transcatheter pathway gets expensive. The PRO-TAVI substudy stratified 466 randomized patients by SYNTAX score. The primary composite did not differ by stratum, and deferral reduced bleeding everywhere, which is the honest headline. But above SYNTAX 17, deferral carried a 30.9% versus 14.8% ischemic composite, driven by death and stroke. Post hoc, one quartile, wide confidence interval touching 1.04. Not practice-changing on its own. It does line up with the guidelines: both ACC/AHA 2020 and ESC 2025 list severe CAD requiring CABG as a factor favoring SAVR, and the surgical literature on combined AVR plus CABG has never had to argue about whether to revascularize complete anatomy. If SYNTAX above 17 really marks the point where PCI-first matters, the Heart Team conversation for a 72-year-old with three-vessel disease and severe AS should include a sternotomy, not just a sequencing question.
[NOTABLE] The conduction system pacing registry (retrospective, 466 matched pairs, 24-month median follow-up) found a 43% relative reduction in CV death or HF hospitalization versus RV pacing, all of it from HF admissions. The accompanying editorial calls it promise meeting evidence, which is right: propensity matching cannot fix operator selection. The surgical comparator is not pacemaker-free either. Contemporary SAVR series report new third-degree AV block near 2.5% in tricuspid AS and 6.5% in bicuspid, and new LBBB after SAVR carries its own mortality signal. The gap favors surgery, but it is narrower than TAVR enthusiasts claim and wider than surgeons admit.
Two technical case reports: wire-anchored BA-BASILICA enabling TAVR in type-0 bicuspid AS with cardiogenic shock, and rescue TAVR after a failed Ozaki procedure. Both n=1. Both are reminders that bicuspid remains Class IIb territory in both guidelines, with NOTION-2 showing a numerically worse transcatheter outcome in BAV.
Surgical vs. Transcatheter Comparisons
No head-to-head TAVR versus SAVR data today. The relevant comparison runs through coronary disease: the PRO-TAVI SYNTAX signal says the patients transcatheter therapy handles least well are exactly the ones the ESC 2025 and ACC/AHA 2020 factor tables already route to surgery. A narrative review plus single-center series in lung transplant candidates (29 relevant studies, only six comparing PCI with CABG, 376 revascularized patients total) found higher mortality and three postoperative coronary events in the PCI group with none in the CABG group, though procedure times were longer with surgery. Small, retrospective, heterogeneous, and the authors decline to name a preferred strategy. The pattern recurs: percutaneous approaches win on early morbidity, surgery wins on completeness, and the literature is too thin to adjudicate.
Device & Technology
JenaValve recalled certain TAVR delivery catheters over safety concerns, per Cardiovascular Business. JenaValve is private, and its Trilogy system is the lead candidate for pure aortic regurgitation, where ESC 2025 gives TAVI only a Class IIb for inoperable patients and ACC/AHA 2020 offers nothing. A delivery system recall in a device whose entire value proposition is controlled positioning in a non-calcified annulus is not a small event. A second Cardiovascular Business roundup bundles the accessory recall with sutureless surgical valve coverage and a lab-grown graft readout.
One electrophysiology note with structural relevance: a case report in EHJ Case Reports describes a 25 mm Amulet occluder aborting pulsed field ablation applications on impedance grounds three years after implant, rescued by switching to radiofrequency on the same dual-energy catheter. As left atrial hardware accumulates alongside mitral and tricuspid devices, these metal-energy interactions will come up more often.
Regulatory & Policy
CMS rule changes for TAVR are drawing questions about self-referral, per Medscape. The structural issue is the two-physician evaluation requirement built into the 2019 National Coverage Determination, which was designed precisely to keep the decision to implant separate from the economics of implanting. Loosen it and the Heart Team becomes advisory. Both guidelines make Heart Team review a Class I expectation for AS intervention, and the ESC 2025 expansion of early intervention into asymptomatic patients (Class IIa, LOE A) makes the referral gatekeeping question more consequential, not less: the population eligible for a procedure just grew, and the check on who decides may be shrinking. Watch the comment docket.
Industry & Market
The JenaValve recall and the CMS coverage question point in opposite directions for the sector. A recall at a private AR-focused developer narrows near-term competitive pressure on Edwards and Medtronic in a niche neither dominates. Looser referral rules, if they survive scrutiny, expand procedural volume for everyone with a commercial valve. Meanwhile Oklahoma Heart Institute's 3-star STS/ACC TVT Registry rating is a reminder that public program ratings are now a marketing asset, which is itself part of the referral economics CMS is being asked about.
Financial Analysis
Edwards closed at $85.64, down 0.87%, after underperforming peers Monday despite daily gains, per MarketWatch. The clinical context matters here. Edwards trades at 51x trailing earnings on a thesis that TAVR volumes compound through asymptomatic AS (EARLY TAVR), moderate AS, and tricuspid. Today's PRO-TAVI substudy is a small headwind to the first leg: patients with complex CAD may be routed to surgery rather than to a transcatheter bundle. The CMS self-referral question is a larger one, because the bull case assumes referral frictions keep falling. Boston Scientific is the outlier, down 31.6% over six months and sitting at its 52-week low of $41.39 with a consensus target of $59.72 and a range running to $94. That spread signals analysts have not converged on what the company is worth, which usually means a pipeline question, not a quarter question.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $85.64, down $0.75 (-0.87%); 6-month change +9.62%
- Market cap $49.3B; P/E trailing 50.97, forward 25.36; beta 0.86
- 52-week range $72.40 to $96.29; 5-day range $82.43 to $87.30
- Analyst target $101.96 (range $84 to $110, 26 analysts); consensus buy
- Next earnings November 4, EPS est $0.74, revenue est $1.68B
- Commentary: the SAPIEN franchise still carries the valuation. EARLY TAVR and the ESC 2025 move to Class IIa early intervention are the volume story; the 51x trailing multiple leaves no room for a reimbursement surprise.
Medtronic (MDT)
- Close $91.93, flat on the day; 6-month change +6.28%
- Market cap $117.6B; P/E trailing 22.59, forward 14.34; beta 0.57
- 52-week range $73.31 to $106.33
- Analyst target $104.44 (range $85 to $121, 25 analysts); consensus buy
- Next earnings November 17, EPS est $1.33, revenue est $9.48B
- Commentary: Evolut's self-expanding design carries the highest permanent pacemaker rate among contemporary platforms, which makes today's conduction system pacing registry a quiet positive. If CSP neutralizes the heart failure cost of post-TAVR pacing, one of the standing arguments against self-expanding valves in younger patients weakens.
Abbott (ABT)
- Close $102.08, up $0.26 (+0.26%); 6-month change +2.74%
- Market cap $177.8B; P/E trailing 32.93, forward 16.83; beta 0.58
- 52-week range $81.97 to $133.34
- Analyst target $120.72 (range $103 to $135, 26 analysts); consensus strong buy
- Next earnings October 21, EPS est $1.42, revenue est $13.00B
- Commentary: MitraClip and TriClip are the structural heart engine. The ESC 2025 upgrade of M-TEER to Class I for ventricular secondary MR and Class IIa for transcatheter tricuspid are European tailwinds that have not yet been matched by an ACC/AHA update.
Boston Scientific (BSX)
- Close $43.21, down $0.63 (-1.44%); 6-month change -31.61%
- Market cap $62.6B; P/E trailing 17.49, forward 12.79; beta 0.57
- 52-week range $41.39 to $105.65, now at the low
- Analyst target $59.72 (range $44 to $94, 29 analysts); consensus buy
- Next earnings October 28, EPS est $0.75, revenue est $5.11B
- Commentary: the worst six-month performance in the group by a wide margin, trading at its 52-week floor. ACURATE neo2's withdrawal from the US pathway removed BSX from the aortic conversation; the structural heart story now rests on WATCHMAN and the tricuspid pipeline.
Anteris Technologies (AVR.AX)
- Close A$9.43, down A$0.16 (-1.67%); 6-month change +20.90%
- Market cap $0.9B; forward P/E -4.35 (pre-revenue)
- 52-week range A$5.20 to A$15.47
- Analyst target A$13.00 (single analyst); no formal consensus
- Commentary: DurAVR's single-piece ADAPT tissue leaflet is a durability bet in a field where the 10-year structural valve deterioration question is still open. Pre-revenue, single-analyst coverage, and a 52-week range spanning a 3x. Treat the chart accordingly.
Market outlook: the sector splits cleanly between companies levered to indication expansion (Edwards, Abbott) and companies that have lost a lane (Boston Scientific). Today's news cuts across both. A CMS rule that loosens referral gatekeeping lifts procedural volume broadly; a CMS rule that invites self-referral scrutiny and litigation does not. The clinical evidence driving valuations is still outrunning the guideline consensus in the US, where ACC/AHA 2020 has not incorporated DEDICATE, EARLY TAVR, RESHAPE-HF2, or TRILUMINATE. That gap is where the next repricing happens.
Clinical Trial Updates
Aortic
- NCT07872020 (SYMMETRY): SYMmetric Valve fraME Expansion To Reduce hYpoattenuated Leaflet Thickening After Balloon-expandable TAVI. Status: not yet recruiting. Phase: NA. Enrollment: 422. Sponsor: Erasmus Medical Center. Intervention: double-TAP post-dilatation. Updated October 13. Worth attention because HALT remains the unresolved mechanistic link between frame asymmetry, subclinical leaflet thrombosis, and long-term structural valve deterioration. A 422-patient randomized test of a technique modification (not a new device) is the kind of trial the field needs more of and funds less often.
- [LANDMARK] NCT05078619 (PRO-TAVI): PCI Before TAVI, 466 patients with significant CAD randomized to PCI deferral versus pre-TAVR PCI. The main trial reported deferral as safe at one year; today's SYNTAX substudy qualifies that in the >17 quartile. An accompanying perspective piece and editorial both frame the open question as which patients benefit, not whether the strategy works on average.
No mitral repair, mitral replacement, tricuspid repair, or tricuspid replacement trials posted status changes in today's registry pull. REPAIR-MR, PRIMARY, TRILUMINATE Pivotal, CLASP TR, APOLLO, and TRISCEND II remain the registrations to watch for the next readout cycle.
Social & Conference Highlights
EACTS is in session and today's feed carried no late-breaking valve trial, no simultaneous publication, and no manufacturer release tied to the meeting. That is the honest report. The JACC: Cardiovascular Interventions issue that landed today was an interventional cardiology issue, not a surgical one: PRO-TAVI, conduction pacing, STEMI revascularization timing, and the OMI/NOMI reframing of NSTEMI triage. Two items from that issue bear on valve practice indirectly. The NCDR CathPCI analysis of intraprocedural cardiac arrest across 3,956,840 PCIs found severe aortic stenosis among the independent predictors, with risk-adjusted IPCA rising from 0.79% to 0.95% between 2018 and 2023 and in-hospital death at 40.5%. If untreated severe AS raises arrest risk in the cath lab, that is an argument for valve-first sequencing in exactly the patients PRO-TAVI's deferral arm now looks worst in. The meta-analysis of immediate versus staged complete revascularization in STEMI (4 RCTs, 2,651 patients, HR 1.50 for one-year death with immediate) is a useful caution about doing everything at once.
The next useful data point is whether CMS actually moves the two-physician requirement, because that single line in the NCD does more to shape US TAVR volume than any trial on today's list. Watch the docket, and watch whether the ACC/AHA writing committee signals a timeline for incorporating EARLY TAVR, DEDICATE, and TRILUMINATE. Europe moved in 2025. The US guideline is now five years stale on a field that reprices annually.